US 11,679,115 B2
Topical compositions and methods for treating psoriasis
Gordon J. Dow, Greenbrae, CA (US); Radhakrishnan Pillai, Santa Rosa, CA (US); and Varsha D. Bhatt, San Francisco, CA (US)
Assigned to Bausch Health Ireland Limited, Dublin (IE)
Filed by Bausch Health US, LLC, Bridgewater, NJ (US)
Filed on Jan. 21, 2021, as Appl. No. 17/154,591.
Application 17/154,591 is a continuation of application No. 16/377,540, filed on Apr. 8, 2019, abandoned.
Application 16/377,540 is a continuation of application No. 15/173,961, filed on Jun. 6, 2016, granted, now 10,251,895, issued on Apr. 9, 2019.
Claims priority of provisional application 62/181,481, filed on Jun. 18, 2015.
Prior Publication US 2021/0145847 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 9/06 (2006.01); A61K 31/192 (2006.01); A61K 47/26 (2006.01); A61K 9/12 (2006.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01); A61K 9/107 (2006.01); A61K 31/4436 (2006.01)
CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 9/12 (2013.01); A61K 31/192 (2013.01); A61K 31/4436 (2013.01); A61K 45/06 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 17 Claims
 
1. A topical pharmaceutical composition for treating psoriasis, the composition comprising:
(a) halobetasol propionate at a concentration of about 0.01% by weight of the composition;
(b) tazarotene at a concentration of about 0.045% by weight of the composition; and
(c) a dermatologically acceptable carrier comprising:
diethyl sebacate at a concentration of about 2.5% to 3.5% by weight of the composition, a mineral oil at a concentration of about 7.5% to 8.5% by weight of the composition, carbomer copolymer type B at a concentration of about 0.3% to 0.5% by weight of the composition,
carbomer homopolymer type A at a concentration of about 0.5% to about 0.7% by weight of the composition, and
purified water.